These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38062630)

  • 21. L-dopa treatment increases oscillatory power in the motor cortex of Parkinson's disease patients.
    Cao C; Li D; Zhan S; Zhang C; Sun B; Litvak V
    Neuroimage Clin; 2020; 26():102255. PubMed ID: 32361482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
    Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS
    J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
    Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Reyns N; Blond S; Guieu JD; Destée A; Defebvre L
    Brain; 2004 Feb; 127(Pt 2):408-19. PubMed ID: 14691060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The long-duration action of levodopa may be due to a postsynaptic effect.
    Barbato L; Stocchi F; Monge A; Vacca L; Ruggieri S; Nordera G; Marsden CD
    Clin Neuropharmacol; 1997 Oct; 20(5):394-401. PubMed ID: 9331515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease.
    Ling H; Massey LA; Lees AJ; Brown P; Day BL
    Brain; 2012 Apr; 135(Pt 4):1141-53. PubMed ID: 22396397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of Parkinson's disease and levodopa on adaptation of anticipatory postural adjustments.
    Hall LM; Brauer SG; Horak F; Hodges PW
    Neuroscience; 2013 Oct; 250():483-92. PubMed ID: 23867768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
    Nutt JG; Carter JH
    Neurology; 2000 Jan; 54(1):247-50. PubMed ID: 10636162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F; Rabey JM
    Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The subacute levodopa test for evaluating long-duration response in Parkinson's disease.
    Quattrone A; Zappia M; Aguglia U; Branca D; Colao R; Montesanti R; Nicoletti G; Palmieri A; Parlato G; Rizzo M
    Ann Neurol; 1995 Sep; 38(3):389-95. PubMed ID: 7668824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease.
    Bastian AJ; Kelly VE; Perlmutter JS; Mink JW
    Mov Disord; 2003 Sep; 18(9):1008-17. PubMed ID: 14502668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of subthalamic nucleus stimulation and levodopa on decision-making in Parkinson's disease.
    Atkinson-Clement C; Cavazzini É; Zénon A; Witjas T; Fluchère F; Azulay JP; Baunez C; Eusebio A
    Mov Disord; 2019 Mar; 34(3):377-385. PubMed ID: 30681186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypomimia in Parkinson's disease: an axial sign responsive to levodopa.
    Ricciardi L; De Angelis A; Marsili L; Faiman I; Pradhan P; Pereira EA; Edwards MJ; Morgante F; Bologna M
    Eur J Neurol; 2020 Dec; 27(12):2422-2429. PubMed ID: 32702196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of patient rated treatment response with measured improvement in Parkinson's disease.
    Davidson MB; McGhee DJ; Counsell CE
    J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):1001-5. PubMed ID: 22626942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
    Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
    Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.